Clinical Trial Update: Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of two HIV vaccine candidates, ChAdV63.HIVconsv and MVA.HIVconsv, in individuals recently infected with HIV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ChAdV63.HIVconsv
• MVA.HIVconsv

Snippet

Sponsor: IrsiCaixa | Conditions: HIV | Phase 1 | Status: COMPLETED